Vaccine and Infectious Diseases Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.
Agency for Science, Technology and Research (A∗STAR), Singapore Immunology Network (SIgN), Singapore, Singapore.
Cell Rep Med. 2020 Jun 23;1(3):100039. doi: 10.1016/j.xcrm.2020.100039.
Growing evidence indicates a role for the gut microbiota in modulating anti-tumor treatment efficacy in human cancer. Here we study mucosa-associated invariant T (MAIT) cells to look for evidence of bacterial antigen recognition in human colon, lung, and kidney carcinomas. Using mass cytometry and single-cell mRNA sequencing, we identify a tumor-infiltrating MAIT cell subset expressing CD4 and Foxp3 and observe high expression of CD39 on MAIT cells from colorectal cancer (CRC) only, which we show to be expressed specifically after TCR stimulation. We further reveal that these cells are phenotypically and functionally exhausted. Sequencing data show high bacterial infiltration in CRC tumors and highlight an enriched species, with capability to activate MAIT cells in a TCR-dependent way. Our results provide evidence of a MAIT cell response to microbial antigens in CRC and could pave the way for manipulating MAIT cells or the microbiome for cancer therapy.
越来越多的证据表明,肠道微生物群在调节人类癌症的抗肿瘤治疗效果方面发挥着作用。在这里,我们研究粘膜相关不变 T (MAIT) 细胞,以寻找人类结肠癌、肺癌和肾癌中细菌抗原识别的证据。使用质谱流式细胞术和单细胞 mRNA 测序,我们鉴定出一种肿瘤浸润性 MAIT 细胞亚群,其表达 CD4 和 Foxp3,并观察到仅来自结直肠癌 (CRC) 的 MAIT 细胞高表达 CD39,我们表明这是在 TCR 刺激后特异性表达的。我们进一步揭示这些细胞在表型和功能上是耗竭的。测序数据显示 CRC 肿瘤中有大量细菌浸润,并突出了一种丰富的物种,具有以 TCR 依赖的方式激活 MAIT 细胞的能力。我们的研究结果为 CRC 中 MAIT 细胞对微生物抗原的反应提供了证据,并为操纵 MAIT 细胞或微生物组进行癌症治疗铺平了道路。